Aptorum Group Ltd (APM)
NGM: APM
· Precio en tiempo real · USD
0.70
n/a (n/a)
Al cierre: Aug 18, 2026, 2:53 PM
Aptorum Group Ltd (APM) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 0.5 |
| Capitalización de mercado | 570.06K |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -1.36M |
| Beta | 0.17 |
| EPS (TTM) | -1.9 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -0.99 |
| P/B (TTM) | 0.02 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 0.83 |
| Volumen | 195,145 |
| Volumen medio (20D) | 81,270 |
| Abierto | 0.70 |
| Anterior Cerrar | n/a |
| Rango del día | 0.60 - 0.74 |
| Rango de 52 semanas | 0.60 - 44.70 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de APM
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the t...
Industria Biotechnology
Sector Healthcare
IPO Fecha Jul 17, 2026
Empleados 1
Bolsa de Valores NGM
Símbolo bursátil APM
Sitio web https://www.aptorumgroup.com
Desempeño financiero
En 2025, los ingresos de Aptorum Ltd fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -1.36M, una disminución de -68.06%.
Estados financieros
Página 1 de 2